Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
Status:
Terminated
Trial end date:
2009-09-22
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and efficacy of LBH589B in adult participants with
refractory/resistant Cutaneous T-Cell Lymphoma and prior Histone Deacetylase (HDAC) inhibitor
therapy.